Selective Platelet-derived Growth Factor Receptor Kinase Blockers Reverse sis-Transformation

Marina Kovalenko,² Aviv Gazit,² Annette Böhmer, Charlotte Rorsman, Lars Rönnstrand, Carl-Henrik Heldin, Johannes Waltenberger, Frank-D. Böhmer,³ and Alexander Levitzkii

Max-Planck Society. Research Group "Growth Factor Signal Transduction." Medical Faculty. Friedrick-Schiller University, Druckendorfer Str. 1, D 07747 Jena, Germany [M.K., F.-D.B.]; The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Givat Ram, Jerusalem 91904, Israel [A.G., A.L.]; Institute of Biochemistry. Medical Faculty. Friedrick-Schiller University, Lohbnerstr. 3, D 07743 Jena, Germany [A.B.]; Ludwig Institute for Cancer Research, Uppsala Branch, Box 265, S-75124 Uppsala, Sweden [C.R., L.R., C.H.H.]; and Department of Medicine II, Ulm University Medical Center, D 89081 Ulm, Germany [J.W.]

ABSTRACT

A novel class of tyrosine kinase blockers represented by the tyrphostins AG1295 and AG1296 is described. These compounds inhibit selectively the platelet-derived growth factor (PDGF) receptor kinase and the PDGF-dependent DNA synthesis in Swiss 3T3 cells and in porcine aorta endothelial cells with 50% inhibitory concentrations below 5 and 1 μM, respectively. The PDGF receptor blockers have no effect on epidermal growth factor receptor autophosphorylation; weak effects on DNA synthesis stimulated by insulin, by epidermal growth factor, or by a combination of both; and an order of magnitude weaker blocking effect on fibroblast growth factor-dependent DNA synthesis. AG1296 potently inhibits signal transduction of human PDGF-α- and β-receptors as well as of the related stem cell factor receptor (c-KIT) but has no effect on autophosphorylation of the vascular endothelial cell growth factor receptor KDR or on DNA synthesis induced by vascular endothelial growth factor in porcine aorta endothelial cells. Treatment by AG1296 reverses the transformed phenotype of sis-transfected NIH 3T3 cells but has no effect on src-transformed NIH 3T3 cells or on the activity of the kinase p60src (527) immunoprecipitated from these cells. These potent and selective compounds represent leads for the development of novel agents to combat tumors driven by PDGF or to inhibit PDGF action in other diseases in which PDGF plays a key role, such as restenosis.

INTRODUCTION

PDGF is a potent mitogen for mesenchymal, glial, and capillary endothelial cells (see Refs. 1 and 2 for reviews). The three isoforms of PDGF, PDGF-AA, PDGF-AB, and PDGF-BB, interact differentially with structurally related receptors designated α- and β-receptors; each of the receptors has an extracellular part with 5 immunoglobulin-like domains and an intracellular part with a tyrosine kinase domain containing a characteristic insert sequence (3–5). The tyrosine kinase activity of the receptors is essential for transmission of the mitogenic signal into the cell (6). PDGF and its receptors participate in various physiological processes such as embryonal development and wound healing. An abnormally high activity of PDGF is believed to play a central role in the etiology of certain adverse pathophysiological situations, such as atherosclerosis and restenosis (7, 8), as well as in other nonmalignant diseases such as pulmonary fibrosis (9), glomerular nephritis (10), and rheumatoid arthritis (11). Moreover, the PDGF

B-chain was acquired as the sis oncogene by the acutely transforming simian sarcoma virus (12, 13). The expression of a PDGF-like growth factor in cells infected with simian sarcoma virus or transfected with the sis oncogene leads to their transformation due to the persistent autocrine stimulation of the resident PDGF receptors. Furthermore, certain human tumors possess PDGF receptors and express the genes for PDGF which suggests that autocrine growth stimulation via PDGF receptors contributes to the malignant phenotype of these tumors (2, 14). The fact that PDGF is likely to be involved in the development of certain disorders has prompted the search for agents to block the action of PDGF. The approaches for interference with PDGF-induced signaling include peptides competing with PDGF for receptor binding (15), dominant negative mutants of PDGF (16, 17) or of PDGF receptor (18), and low molecular weight blockers of the receptor tyrosine kinase activity known as tyrphostins (19). Certain tyrphostins which block PDGF-dependent proliferation of rabbit vascular smooth muscle cells (20) and of human bone marrow fibroblasts (21) have already been reported. In this study we describe a novel class of potent tyrphostins which possess the quinoxaline moiety, which show high selectivity towards the PDGF receptor kinase, and which reverse the transformation of fibroblasts transformed with the oncogene sis. These compounds are new leads for drugs which could potentially combat restenosis, atherosclerosis, and tumors in which PDGF plays a prominent role.

MATERIALS AND METHODS

Synthesis. The synthetic methods and analytical data of the used compounds will be described elsewhere. The formulas of the tyrphostins used in this study are shown in Fig. 1.

Cells and Reagents. Swiss 3T3 cells (obtained from E. Rozengurt, London, United Kingdom) and NIH 3T3 cells, stably transfected with a constitutively active mutant (F527) of chicken c-sr矸 gene (generously provided by S. Courtneidge, Heidelberg, Germany), were grown in DMEM supplemented with 4 g/liter glucose, glutamic acid, antibiotics, and 10% FCS. sis-transfected NIH 3T3 fibroblasts (kindly provided by Dr. S. Aaronson, Bethesda, MD) were cultured in the same medium in the presence of 0.4 mg/ml geneticin. Porcine aortic endothelial cells stably expressing human PDGF β-receptors (22), α-receptors (23), Kit/SCF receptor (24), or KDR (25) have been described previously and were cultured in Ham’s F-12 medium supplemented with geneticin (0.4 mg/ml) and 10% FCS. All cell culture reagents were from Gibco. PDGF was the recombinant human BB homodimer. Murine EGF, human VEGF, and recombinant human basic FGF were kindly provided by E. Spitzer (Berlin, Germany), D. Gospodarowicz (San Francisco, CA), and B. Stoyanov (Sofia, Bulgaria), respectively. The anti-PDGF receptor antiserum DIG1 was raised against a peptide corresponding to amino acid residues 1075–1089 in the human PDGF α-receptor but recognized PDGF α- and β-receptors equally well.⁶ The antiserum PDGF-R3 against PDGF receptor (5) and antisera against FGF receptor 1 (26) and KDR (25) have been described. [methyl-³²H]Thymidine and [γ-³²P]ATP were purchased from DuPont/NEN (Dreieich, Germany).

Received 7/5/94; accepted 9/28/94.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1. Part of this work was supported by Research Scholarship Bo 10431-1 to F.-D.B. and by a grant from SUGEN, Inc. (Redwood City, CA) to A. L.

2. The two first authors contributed equally to the study.

3. To whom correspondence regarding the functional studies should be addressed.

4. To whom requests for reprints and correspondence regarding the chemical aspects should be addressed.

5. The abbreviations used are: PDGF, platelet-derived growth factor; EGF, epidermal growth factor; FGF, fibroblast growth factor; VEGF, vascular endothelial growth factor; DMEM, Dulbecco’s modified Eagle’s medium; FCS, fetal calf serum; Heps, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; DMSO, dimethyl sulfoxide; SDS, sodium dodecyl sulfate; PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buffered saline; PAE, porcine aortic endothelial cells; SCF, stem cell factor; TCA, trichloroacetic acid; IC50, 50% inhibitory concentration.

6. L. J. Goez, unpublished data.

6106
Membrane Autophosphorylation Assays. Membranes were prepared from confluent cultures of Swiss 3T3 cells as described (27). For measuring receptor autophosphorylation, 10 μg membrane protein per assay were incubated for 20 min on ice in the presence of 1.2 μg/ml EGF or 2 μg/ml PDGF, or both; 50 mM Hepes (pH 7.5); and 3 mM MnCl₂ (final concentrations) in a volume of 45 μl. In order to test the effects of tyrphostins, these were added in a volume of 0.5 μl (in DMSO; final concentration, 0.5%) 15 min before addition of the growth factors. Phosphorylation was initiated by addition of [γ-32P]ATP (5 μl, 3–5 μCi; final concentration, 2 μM) and terminated after 2 min by addition of 10 μl of a solution containing 6% SDS, 30% β-mercaptoethanol, 40% glycerol, and 0.5 mg/ml bromophenol blue. The samples were heated for 5 min at 95°C and subjected to SDS-PAGE according to the method of Laemmli (28) using 10% acrylamide gels. The gels were stained and dried and subjected to autoradiographic analysis.

For quantification of radioactivity in electrophoresis gels, a Phosphorimager (Molecular Dynamics, Fuji, or Bio-Rad) was used according to the instructions of the manufacturers. To obtain autoradiograms, objects were exposed to X-ray film (Fuji RX or Kodak X-OMAT) with intensifying screens at ~70°C.

Assay of Receptor Autophosphorylation in Intact Cells. Confluent Swiss 3T3 cells in 24-well plates (Nunc) were incubated for 20–24 h in serum-free DMEM. Subsequently, tyrphostins were added at concentrations ranging from 0 to 100 μM (final DMSO concentration, 0.5%) and the incubation was continued for 6–8 h. The cells were then stimulated with 100 ng/ml PDGF-BB for 5 min at room temperature or 600 ng/ml EGF for 2.5 min on ice. The growth factor treatment was terminated by washing twice with ice-cold PBS and the cells were scraped off the wells in 60 μl lysis buffer containing 20 mM Hepes (pH 7.4), 150 mM NaCl, 1% Triton X-100, 10 mM sodium pyrophosphate, 50 mM NaF, 2 mM sodium o-vanadate, 20 μM zinc acetate, 10 mM EDTA, 2 mM [ethylenebis(oxyethylenenitro)]tetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, and 5 μg/ml leupeptin. sis-transfected cells were grown to near confluency and treated with the tyrphostins in the presence of DMEM/10% FCS for 48 h. Cell extracts were obtained as above.

The cell lysates were clarified by centrifugation (cooled microfuge, 17,000 rpm, 15 min) and analyzed by SDS-PAGE (6.5% gels) and immunoblotting with anti-phosphotyrosine antibodies (either PY 20, ICN and subsequently a peroxidase-coupled secondary antibody, or RC20-peroxidase conjugate; Affiniti, Nottingham, United Kingdom). The blots were developed with a chemiluminescence detection system (Western Light, Tropix, or ECL; Amersham). In some experiments PDGF receptors were immunoprecipitated with PDGF-R3 or DIG1 antibodies as described (23) prior to the analysis by immunoblotting with anti-phosphotyrosine antibodies. To measure autophosphorylation of PDGF α or PDGF β-receptors expressed in PAE cells, subconfluent cultures were treated with serum-free medium in the presence of various concentrations of the inhibitors or DMSO for 1 hour at 37°C. Then, PDGF-AA or PDGF-BB were added at 50 ng/ml and the incubation was continued for 5 min. The cultures were placed on ice and the cells were lysed with ice-cold lysis buffer containing 0.5% Triton X-100, 0.5% sodium deoxycholate, 0.15 M NaCl, 20 mM Tris/HCl (pH 7.4), 5 mM EDTA, 30 mM sodium pyrophosphate, 1 mM phenylmethylsulfonyl fluoride, 1% Trasylol, and 200 μM sodium o-vanadate. The lysates were then incubated for 1 h at 4°C with wheat germ agglutinin-Sepharose beads (29). The beads were washed 3 times with the lysis buffer and once with H₂O and were then eluted with SDS-PAGE sample buffer. Then, receptor phosphorylation was analyzed by SDS-PAGE (7.5% gels) and immunoblotting with anti-phosphotyrosine antibodies.
To measure autophosphorylation of KDR expressed in PAE cells, subconfluent cultures were treated with Ham's F-12 medium containing 0.5% FCS for 16 h in the presence of the inhibitors or DMSO. Then, the cells were treated with 50 ng/ml VEGF for 8 min at 37°C and subsequently extracted as described above. The receptors were immunoprecipitated with a KDR-specific antibody (25) and the immunoprecipitates were analyzed by SDS-PAGE and immunoblotting with anti-phosphotyrosine antibodies.

**Src Activity Assay.** src-transformed NIH 3T3 cells were grown in 24-well plates to confluency; rinsed twice with a solution containing 20 mM Tris, 0.1 mM sodium o-vanadate, and 150 mM NaCl (pH 7.5); and lysed in 100 µl/well of lysis buffer containing 20 mM Tris (pH 8.0), 150 mM NaCl, 1% Nonidet P-40, 2.5 mM EDTA, 10 mM NaF, 1% Trasylol, and 20 µM leupeptin. The lysate was clarified by centrifugation and subjected to immunoprecipitation with the anti-Src monoclonal antibody 327 (Oncogene Science; 0.5 µg anti-plates to confluency; rinsed twice with a solution containing 20 mMTris, 0.1 mM sodium o-vanadate, and 150 mM NaCl (pH 7.5); and lysed in 100 µl/well of lysis buffer containing 20 mM Tris (pH 8.0), 150 mM NaCl, 1% Nonidet P-40, 2.5 mM EDTA, 10 mM NaF, 1% Trasylol, and 20 µM leupeptin. The lysate was clarified by centrifugation and subjected to immunoprecipitation with the anti-Src monoclonal antibody 327 (Oncogene Science; 0.5 µg anti-body/80 µg protein) for 1 h at 4°C. Then, goat anti-mouse IgG (Sigma; 0.2 µg/0.5 µg monoclonal antibody 327) was added and incubation was continued for 30 min followed by another 40 min of incubation with 10 µl of protein A-Sepharose CL-4B (Pharmacia). The immunoprecipitates were washed 5 times with the lysis buffer and twice with kinase buffer containing 40 mM sodium o-vanadate, and 150 mMNaCl (pH 7.5); and lysed in 100 µl/well (Nunc, 1—2 × 10^6 cells/well) and cultured for 3 days in DMEM supplemented with 10% FCS. Thereafter, the medium was changed to serum-free DMEM for 16—18 h. Then, tyrosphostins were added at the indicated concentrations for 6—8 h (final DMSO concentration, 0.5%). Growth factors (EGF, PDGF, or basic FGF at 10 ng/ml; insulin at 1 µg/ml) and [methyl-3H]thymidine (final concentration, 1 µCi/ml, 2 µM) were added together and cultivation was continued for 20—24 h. Then, the cells were washed twice with PBS, treated for 10 min with 5% TCA, washed once with TCA, twice with PBS, and twice with methanol (all at 4°C) and dried. 0.5 ml NaOH (0.1 N) containing 1% SDS was added per well, the plates were incubated for 30 min at 37°C, and 0.2-ml aliquots were taken for measuring radioactivity.

To test the reversibility of the inhibitory effect of tyrophostins, the cells were washed once for 30 min with serum-free DMEM after 6—8 h of preincubation with the inhibitors. Then, growth factors and [3H]thymidine were added and the procedure was continued as described above.

DNA synthesis in PAE cells expressing PDGF receptors or Kit/SCF receptor was measured as described (23, 24). Briefly, the cells were serum deprived for 48 h. Then, the medium was changed to serum-free medium containing 16—18 h. Then, tyrphostins were added at the indicated concentrations for 6—8 h (final DMSO concentration, 0.5%). Growth factors (EGF, PDGF, or basic FGF at 10 ng/ml; insulin at 1 µg/ml) and [methyl-3H]thymidine (final concentration, 1 µCi/ml, 2 µM) were added together and cultivation was continued for 20—24 h. Then, the cells were washed twice with PBS, treated for 10 min with 5% TCA, washed once with TCA, twice with PBS, and twice with methanol (all at 4°C) and dried. 0.5 ml NaOH (0.1 N) containing 1% SDS was added per well, the plates were incubated for 30 min at 37°C, and 0.2-ml aliquots were taken for measuring radioactivity.

To test the reversibility of the inhibitory effect of tyrophostins, the cells were washed once for 30 min with serum-free DMEM after 6—8 h of preincubation with the inhibitors. Then, growth factors and [3H]thymidine were added and the procedure was continued as described above.

DNA synthesis in PAE cells expressing PDGF receptors or Kit/SCF receptor was measured as described (23, 24). Briefly, the cells were serum deprived for 48 h. Then, the medium was changed to serum-free medium containing 16—18 h. Then, tyrphostins were added at the indicated concentrations for 6—8 h (final DMSO concentration, 0.5%). Growth factors (EGF, PDGF, or basic FGF at 10 ng/ml; insulin at 1 µg/ml) and [methyl-3H]thymidine (final concentration, 1 µCi/ml, 2 µM) were added together and cultivation was continued for 20—24 h. Then, the cells were washed twice with PBS, treated for 10 min with 5% TCA, washed once with TCA, twice with PBS, and twice with methanol (all at 4°C) and dried. 0.5 ml NaOH (0.1 N) containing 1% SDS was added per well, the plates were incubated for 30 min at 37°C, and 0.2-ml aliquots were taken for measuring radioactivity.

To test the reversibility of the inhibitory effect of tyrophostins, the cells were washed once for 30 min with serum-free DMEM after 6—8 h of preincubation with the inhibitors. Then, growth factors and [3H]thymidine were added and the procedure was continued as described above.

DNA synthesis in PAE cells expressing PDGF receptors or Kit/SCF receptor was measured as described (23, 24). Briefly, the cells were serum deprived for 48 h. Then, the medium was changed to serum-free medium containing.
either 5 ng/ml PDGF-AA or PDGF-BB or 10 ng/ml SCF, respectively, [3H]thymidine, and the inhibitors or DMSO. Incorporated [3H]thymidine was measured after 24 h. KDR expressing PAE cells were subjected to serum deprivation for 64 h. After 40 h of serum deprivation tyrosphostins were added and during the last 20 h VEGF (2.5 ng/ml) was present. Two h prior to precipitation with ice-cold 10% TCA, [3H]thymidine was added. The samples were processed for liquid scintillation counting as described above.

**Cell Proliferation Assays.** Cells were seeded in 24-well plates (5000 cells/well) in DMEM/10% FCS. On the next day the medium was changed to DMEM/2% FCS with or without growth factors and tyrosphostins were added as described above. Three days later the cells were counted in a hemocytometer.

**Soft Agar Assays.** Cells (4000 cells/ml) were cultured in 0.3% agar in the presence of DMEM/10% FCS on a base layer of 0.5% agar in the presence or absence of tyrosphostins. After 2 weeks the formed colonies were counted.

### RESULTS

**Screening of Tyrosphostins.** Tyrosphostins from various structural families (Fig. 1) were tested for their potency to inhibit ligand-induced autophosphorylation of PDGF receptor and EGF receptor in Swiss 3T3 cell membranes which harbor both receptors. Membranes were incubated simultaneously with EGF, PDGF-BB, and [γ-32P]ATP in the absence or presence of the compounds to be tested. Autophosphorylation of the receptors was monitored by SDS-PAGE and autoradiography. In Fig. 2 the comparison of 6 tyrosphostins, representing several families, is shown as an example. The compound AG34 had little effect on autophosphorylation of either of the receptors, AG775 inhibited EGF receptor autophosphorylation but had no effect on PDGF receptor autophosphorylation, and AG805 inhibited both receptor kinases with similar efficacy. Work on these three compounds was stopped at this point. Tyrosphostins AG808, AG1295, and AG1296 abolished autophosphorylation of the PDGF receptor completely whereas the autophosphorylation of the EGF receptor was only slightly inhibited by AG808 or not at all affected by AG1295 and AG1296 (Fig. 2). The small group of compounds which scored positive in this screening were then tested for their ability to selectively inhibit PDGF receptor autophosphorylation and PDGF-stimulated DNA synthesis in intact cells. In these assays, only AG1295 and AG1296 scored positive and AG1152 partially positive (Table 1). AG1295 and AG1296 were further characterized (see below) but since the latter was slightly more potent (Table 1) only the data for AG1296 are presented. Both 1295 and 1296 belong to quinoxaline type tyrosphostins, different from the previously characterized benzenemalononitrile tyrosphostins (19, 20), represented by AG34 and the indole tyrosphostins (21) represented by AG805 and AG808.

**Selective Inhibition of PDGF Receptor Kinase and PDGF-stimulated Cell Growth by AG1296 in Swiss 3T3 Cells.** Fig. 3A depicts the dose-response curve for inhibition of the PDGF receptor kinase in Swiss 3T3 cell membranes by AG1296. Whereas the compound inhibited the PDGF receptor autophosphorylation with an IC50 of 0.3–0.5 μM (Fig. 3A), the EGF receptor kinase in the same membranes was not inhibited up to the concentration of 100 μM (Fig. 3A and data not shown). Similar results were obtained comparing the potency of AG1296 to inhibit PDGF receptor autophosphorylation and EGF receptor autophosphorylation in intact cells (Fig. 3B; Table 1): PDGF receptor autophosphorylation was strongly inhibited at submicromolar concentration of AG1296; whereas EGF receptor autophosphorylation was not blocked even at 100 μM. AG1296 was also highly inhibitory towards PDGF-induced mitogenesis but had a minimal effect on mitogenesis mediated by EGF, insulin, or a combination of these factors (Fig. 4A). The inhibition of PDGF-stimulated DNA synthesis by AG1296 was fully reversible (Fig. 5). The mitogenic effect of basic FGF on Swiss 3T3 cells was clearly inhibited by AG1296 (Fig. 4A), albeit with an IC50 of 12.3 ± 3.1 μM (mean of 5 experiments ± SD) which is 1 order of magnitude higher than that for

### Table 2 Effect of the tyrosphostin AG1296 on the DNA synthesis in porcine aortic endothelial cells expressing different human growth factor receptors

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Ligand</th>
<th>IC50 (μM) for inhibition of ligand-stimulated DNA synthesis</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDGF α-receptor</td>
<td>PDGF-AA</td>
<td>1.0</td>
</tr>
<tr>
<td>PDGF β-receptor</td>
<td>PDGF-BB</td>
<td>0.8</td>
</tr>
<tr>
<td>Kit-SCF receptor</td>
<td>SCF</td>
<td>1.8</td>
</tr>
<tr>
<td>KDR-VEGF receptor</td>
<td>VEGF</td>
<td>&gt;10</td>
</tr>
</tbody>
</table>

![Fig. 4](image_url) **Effect of AG1296 on growth of Swiss 3T3 cells stimulated by different growth factors. A. DNA synthesis.** The treatment of cells by AG1296 was performed as described above and in "Materials and Methods." Then, growth factors (PDGF, 10 ng/ml; EGF, 10 ng/ml; insulin, 1 μg/ml; basic FGF, 10 ng/ml as indicated) were added together with [3H]thymidine for 20–24 h and TCA-precipitable radioactivity was measured. The stimulation of [3H]thymidine incorporation induced by PDGF, EGF, insulin plus insulin (Ins), insulin, and basic FGF was 180-, 5-, 225-, 40-, and 88-fold over background, respectively, and was set at 100%. Typical curves as obtained in at least 3 independent experiments are shown. B, cell proliferation. Swiss 3T3 cells were treated with different concentrations of AG1296 in DMEM supplemented with 2% FCS in the absence or presence of PDGF (10 ng/ml), insulin (1 μg/ml), or insulin plus EGF (10 ng/ml). Cell numbers were determined after 3 days. Control values are: no growth factor, 24,000 cells/well; PDGF, 84,500 cells/well; insulin, 74,600 cells/well; insulin/EGF, 92,800 cells/well.

---

6109
PDGF-induced DNA synthesis (1.5 ± 0.7 μM, mean of 5 experiments in direct comparison). AG1296 also potently inhibited PDGF-induced cell growth (IC50 3.2 μM) (Fig. 4B) at a much lower concentration range than that needed for the inhibition of cell growth induced by EGF, insulin, or a combination of both growth factors (IC50 > 25 μM). At higher concentrations of AG1296, however, a general inhibition of cell division was observed.

Effect of AG1296 on Tyrosine Kinase Receptors Expressed in Porcine Aortic Endothelial Cells. To further explore the potency and specificity of AG1296, its effects on various tyrosine kinase receptors expressed in porcine aortic endothelial cells were analyzed. AG1296 was found to inhibit autophosphorylation of both human PDGF α- and PDGF β-receptors (Fig. 6) in intact cells and to inhibit equipotently PDGF α- and PDGF β-receptor-dependent DNA synthesis in cells transfected with either receptor (Table 2). We then examined the effect of tyrphostins on the SCF receptor Kit (31), a close relative of the PDGF receptor, expressed in PAE cells. As shown in Table 2, this receptor is as sensitive to AG1296 as are the PDGF receptors. KDR, another receptor tyrosine kinase which is structurally related to the receptors for PDGF, is expressed on endothelial cells and functions as a receptor for VEGF (32–36). KDR was found to be virtually insensitive to AG1296, at both the level of receptor autophosphorylation (Fig. 6) and VEGF-stimulated DNA synthesis (Table 2).

AG1296 Reverses Cell Transformation Induced by sis but Not by src. sis-transfected fibroblasts acquire a transformed phenotype characterized by the loss of density-dependent growth arrest, the ability to form tumors in nude mice, and the ability to grow in semisolid agar due to activation of PDGF receptors (37, 38). When sis-transformed cells were treated with the tyrphostin AG1296, we observed a dose-dependent change from a non-contact-inhibited phenotype to a flattened, contact-inhibited morphology similar to that of nontransformed NIH 3T3 cells (Fig. 7). This effect is already detectable at 10 μM AG1296 and the reversion of the transformed phenotype is complete at 50 μM. AG1296 also potently inhibits the growth of the sis-transformed NIH 3T3 cells in semisolid agar, with approximately 80% inhibition of colony formation at 5 μM (Table 3).

We then examined whether the sis-antagonizing activity of AG1296 could be attributed to the inhibition of PDGF receptor kinase in the cells harboring the oncogene. To this end, sis-transformed cells were treated with different concentrations of the tyrphostin. The extent of tyrosine phosphorylation of the endogenous PDGF receptors was then evaluated by immunoblotting either in whole cell lysates or after immunoprecipitation of the PDGF receptors with receptor-specific antibodies (Fig. 8). In contrast to normal Swiss 3T3 cells (Fig. 3), activated PDGF receptors were detectable in sis-transformed NIH 3T3 cells in the absence of exogenous PDGF. When the sis-transformed NIH 3T3 cells were treated with AG1296, the autophosphorylation of the PDGF receptors was nearly abolished (Fig. 8). The dose dependence of the inhibition of PDGF receptor autophosphorylation in sis-transfected cells by AG1296 corresponds to the dose-dependent reversal of the transformed morphology of the cells (not shown).

To further explore the specificity of the inhibition of sis transformation by tyrphostin AG1296, we investigated the possible
Table 3 Inhibition of colony formation of sis-transformed cells in semisolid agar by tyrphostin AG1296

<table>
<thead>
<tr>
<th>Treatment</th>
<th>No. of colonies</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>212</td>
<td>100</td>
</tr>
<tr>
<td>DMSO</td>
<td>211</td>
<td>100</td>
</tr>
<tr>
<td>5 μM</td>
<td>21</td>
<td>10</td>
</tr>
<tr>
<td>10 μM</td>
<td>3</td>
<td>1.4</td>
</tr>
<tr>
<td>25 μM</td>
<td>1</td>
<td>0.5</td>
</tr>
<tr>
<td>50 μM</td>
<td>0.5</td>
<td>0.2</td>
</tr>
</tbody>
</table>

Fig. 7. Effect of tyrphostin AG1296 on the morphology of sis-transformed cells. sis-transformed NIH 3T3 cells were treated with DMSO alone (A) or with 50 μM AG1296 (B) for 72 h in DMEM supplemented with 10% FCS. Normal NIH 3T3 cells were also treated with DMSO (C) or AG1296 (D). Microphotographs were taken with a phase contrast microscope. ×300.

effects of the compound on NIH 3T3 cells transfected with an oncogenic variant of c-src (chicken src F527 mutant). Similar to sis-transfected cells, these cells show an irregular growth pattern and grow in semisolid agar (39, 40). No morphological changes of the src-transformed cells could be seen up to a 50 μM dose of the compound AG1296 nor could inhibition of any tyrosine-phosphorylated protein be detected by immunoblotting of whole cell lysates (not shown). To directly test the effect of AG1296 on the Src tyrosine kinase, the p60⁰⁰src(F527) protein was precipitated from cell lysates and the kinase activity was assayed. As shown in Fig. 9, little inhibition of the Src kinase could be detected (25% inhibition at 50 μM AG1296). Independent experiments show that AG34 and its homologue, which have no effect in the PDGF receptor system (Fig. 2), reverse Src F527 induced transformation and block Src kinase activity (41).

Table 3 inhibition of colony formation of sis-transformed cells in semisolid agar by tyrphostin AG1296

DISCUSSION

Low molecular weight tyrosine kinase inhibitors of the tyrphostin type have previously been reported to inhibit PDGF-induced mitogenesis in human bone marrow fibroblasts (21) and in rabbit vascular smooth muscle cells (20). In this study we describe a novel class of tyrphostin derivatives which are more potent and specific in inhibiting PDGF receptor tyrosine kinase, both in normal and sis-transformed murine fibroblasts and in porcine aortic endothelial cells expressing human PDGF α- or β-receptors.

The new class of tyrphostins, represented by AG1296 and AG1295, is much superior to the previously described compounds due to their high potency and excellent selectivity. This is demonstrated by their effect on PDGF-induced cell growth in Swiss 3T3 cells as compared with their effects on cell growth driven by EGF, insulin, a combination of EGF and insulin, or basic FGF. Furthermore, in contrast to the previously described tyrphostins, these compounds have only a negligible effect on p60⁰⁰src(F527) kinase activity and on src-transformed cells. The IC₅₀ for PDGF receptor kinase inhibition in intact cells is slightly lower than the value measured for DNA synthesis (Table 1). This is probably due to the necessarily different experimental conditions; still the selectivity of AG1295 and AG1296 is clear. Close correlation of the inhibition of PDGF receptor tyrosine kinase activity in intact cells and of the DNA synthesis induced by PDGF in both Swiss 3T3 cells and PDGF receptor expressing PAE cells by AG1296 demonstrates that inhibition of the receptor kinase plays a primary role in the inhibition of PDGF-induced growth of both cell lines. Much higher concentrations of AG1296 were required to partially
inhibit DNA synthesis and cell proliferation induced by other growth factors and even then no effect could be measured on their respective receptor kinases. This finding suggests that other intracellular targets, possibly the tyrosine kinases involved in intracellular signaling pathways used by multiple growth factors, might be susceptible to inhibition by AG1296 at higher concentrations of the tyrphostin. No signs of cytotoxicity of AG1296 were observed and the inhibition of PDGF-stimulated DNA synthesis was fully reversible. Among the various pharmacophores examined, the quinoxaline moiety was found to be the most selective and potent (Table 1). The benzenemalononitrile pharmacophore and indole used previously (20, 21), although efficient, are less effective (Table 1). The quinoxaline structure of these tyrphostins serves as a pharmaceutical lead for developing agents for treatment of the disorders involving pathological PDGF-induced cell proliferation. The oncostatic potential of the compounds is indicated by their ability to revert the transformed phenotype of sis-transfected fibroblasts, as judged by cell flattening (Fig. 7) and inhibition of soft agar growth (Table 3). In the sis-transfected cells the inhibition of receptor kinase activity (Fig. 8) and in turn the reversion of the transformed phenotype required higher concentrations of the tyrphostin compared to the concentrations needed to inhibit the kinase in Swiss 3T3 cells and PDGF receptor expressing PAE cells. The higher concentrations might be necessary partially because the assays with sis cells had to be performed in the presence of serum and partially because the majority of PDGF receptors in the sis cells is not at the cell surface (42, 43) and might be thus less readily accessible for the inhibitors. Another potentially interesting target for this novel class of PDGF receptor kinase blockers might be the pathological proliferation and cell migration in relation to atherosclerosis and restenosis (8). In this respect it is of particular interest that compound AG1296 inhibited potently the PDGF receptor kinase but had virtually no effect on the kinase activity of the VEGF receptor KDR. Since PDGF receptors are predominantly expressed in smooth muscle cells (8) whereas the expression of KDR is restricted to the endothelium (35), one would expect a selective inhibition of smooth muscle cell proliferation and migration by AG1296 whereas endothelial cell function may remain unaltered in the presence of the compound. AG1296 or related substances therefore represent candidate drugs for the prevention of restenosis, i.e., the migration (44) and rapid proliferation (45) of smooth muscle cells secondary to percutaneous angioplasty resulting in the narrowing of the arterial lumen and limiting the intermediate and long term success of the treatment of atherosclerotic lesions (46).

There is no effect of compound AG1296 on PDGF binding. The cellular uptake of AG1296 is rapid, since incubation of the cells for 2 min with 50 μM compound is sufficient to block the PDGF receptor kinase completely. This is similar to previously reported behavior of tyrphostins (21, 47). For other tyrphostins an inhibition of the target kinases based on competition with the protein substrate has already been demonstrated (46, 47). The exact mode of PDGF receptor kinase inhibition has not been investigated but the mechanism of EGF receptor kinase and insulin receptor kinase inhibition has been studied in detail (48—51). In these studies it has been shown that some of the blockers are competitive versus the substrate and ATP and others are competitive vis-à-vis the substrate and noncompetitive with respect to ATP. From the high selectivity observed for the quinoxalines repre-

---

*Fig. 8. Effect of tyrphostin AG1296 on autophosphorylation of the PDGF receptor in sis-transformed cells. sis-transformed NIH 3T3 cells were treated for 48 h with DMSO (Lanes 1 and 3) or 50 μM AG1296 (Lanes 2 and 4). Cell extracts were either directly analyzed by SDS-PAGE and immunoblotting with anti-phosphotyrosine antibodies (Lanes 3 and 4) or subjected to immunoprecipitation with anti-PDGF receptor antibody (Lanes 1 and 2) prior to SDS-PAGE and immunoblotting. For comparison, a cell extract of PDGF-stimulated Swiss 3T3 cells was also analyzed (Lane 5).*

---

7 C. Rorsman et al., data not shown.
8 A. Böhmer et al., data not shown.
sent by AG1295 and AG1296, it is likely that their mode of interacting with tyrosine kinases is similar. We observed that receptors closely related to the PDGF receptor were more sensitive to inhibition by AG1296 than more divergent receptor tyrosine kinases. Therefore PDGF α- and β-receptors as well as the closely related Kit/SCF receptor exhibited equal inhibition by AG1296. The more distantly related FGF receptor 1 was more than 1 order of magnitude less sensitive to AG1296 and the EGF receptor, the insulin receptor, and the VEGF receptor KDR which is structurally related to the PDGF receptors were completely refractory to the action of AG1296. Thus, despite some overall similarity between the PDGF receptor and the KDR kinase, they differ in their sensitivity towards kinase inhibitors and one can therefore speculate that both receptors might also differ in their substrate specificity. Work is under way to characterize the mechanism of action of compound AG1296 in detail. The relative sensitivity of the Kit/SCF receptor may cause leukopenia in in vivo experiments, although preliminary experiments did not reveal leukopenia in mice when 20 mg/kg were injected daily (data not shown). Nevertheless, we are now attempting to design derivatives of AG1295 and AG1296 which differentiate between Kit/SCF receptor and PDGF receptor and still retain the high selectivity toward the latter.

ACKNOWLEDGMENTS

We gratefully acknowledge the kind provision of sis-transformed NIH 3T3 cells, Swiss 3T3 cells, and src-transformed NIH 3T3 cells from Drs. Stuart Aaronson, Enrique Rozengurt, and Sara Courtneidge, respectively. Furthermore, we are indebted to Dr. Denis Gospodarowicz for the gift of VEGF, Dr. Eva Spitzer for murine EGF, Boris Stoyanov for recombinant human basic FGF, and Dr. L. Jorge Gnone for anti-PDGF receptor antibodies. We thank Ulrike Mayr for her expert technical assistance.


REFERENCES


PDGF RECEPTOR KINASE BLOCKERS REVERSE s-six-TRANSFORMATION


Selective Platelet-derived Growth Factor Receptor Kinase Blockers Reverse sis-Transformation

Marina Kovalenko, Aviv Gazit, Annette Böhmer, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/54/23/6106

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/54/23/6106. Click on “Request Permissions” which will take you to the Copyright Clearance Center's (CCC) Rightslink site.